Motilin is a peptide hormone, localized in the GI tract, which is primarily responsible for the initiation of the migrating motor complex. These migrating motor complexes help facilitate the movement of indigestible substances through the GI tract.
TZP-201 is a motilin antagonist in development for the treatment of various forms of moderate-to-severe diarrhea. TZP-201 has demonstrated significant reduction in pre- and post-prandial migrating motor complex patterns in preclinical evaluations.
TZP-201 has also demonstrated reduction in the incidence of diarrhea in preclinical models involving irinotecan, a potent chemotherapeutic with high incidence of diarrhea, more effectively than either of two current treatments, octreotide and loperamide.Tranzyme intends to continue to evaluate TZP-201 for treatment of chemotherapy‑induced diarrhea.